Related Experiment Videos
Current management of tonsillar cancer
Eric M Genden1, Alfio Ferlito, Crispian Scully
1Department of Otolaryngology-Head and Neck Surgery, Mount Sinai School of Medicine, New York, New York, USA.
Oral Oncology
|April 5, 2003
Summary
Human papillomavirus (HPV) is an emerging risk factor for tonsil cancer, particularly in younger patients. Early-stage tonsil cancer treatment offers similar survival rates, with primary surgery minimizing long-term side effects.
Area of Science:
- Oncology
- Virology
- Otolaryngology
Background:
- Traditional tonsil cancer risk factors include alcohol and tobacco use.
- A notable percentage of new tonsil cancer cases occur in young patients lacking these traditional risk factors.
- Human papillomavirus (HPV) is increasingly recognized as a potential etiological factor in a subset of tonsil cancer cases.
Purpose of the Study:
- To explore the role of HPV as a risk factor in tonsil cancer.
- To compare treatment modalities for early-stage tonsil cancer.
- To address the challenges in managing advanced tonsil cancer.
Main Methods:
- Review of epidemiological data on tonsil cancer risk factors.
- Analysis of treatment outcomes for early-stage tonsil cancer (surgery vs. radiotherapy).
- Discussion of therapeutic strategies for advanced tonsil cancer.
Main Results:
- HPV represents a distinct risk factor for a subset of tonsil cancer patients.
- Both surgery and radiotherapy achieve similar local-regional control and survival for early-stage disease.
- Primary surgery for early tonsil cancer results in less functional morbidity compared to radiotherapy.
Conclusions:
- HPV is an important consideration in the etiology of tonsil cancer, especially in non-traditional risk groups.
- For early tonsil cancer, primary surgery is preferred to minimize functional morbidity, reserving radiation for recurrent disease.
- Advanced tonsil cancer management remains complex, often requiring multimodality treatment with ongoing challenges in neck and distant metastasis control.